SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel ($INTC) is trending after a strong earnings report, beating expectations and forecasting continued growth. The community is discussing the potential for a short squeeze, the impact of government investments, and new partnerships. Many express confidence in the company's turnaround and future prospects in the semiconductor industry.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is trending due to a recent pullback, prompting debate among investors about whether it represents a buying opportunity or a sign of deeper issues. Community discussions revolve around the stock's support levels, potential for a rebound, and the influence of broader market trends. Some investors remain confident in the company's long-term prospects within the AI and data center sectors, citing significant contracts and growth potential.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending amid speculation and a now-denied report about potential US government investment in quantum computing companies, fueling high trading volume. Community chatter focuses on whether this is a buying opportunity or a pump and dump scheme, while some highlight D-Wave's existing technology and government connections. The stock's volatility reflects broader interest and skepticism surrounding the quantum computing sector.

Newmont Corp. engages in the exploration and acquisition of gold properties, containing copper, silver, lead, zinc or other metals. It operates through the following geographical segments: Canada, Mexico, Suriname, Argentina, Peru, Australia, Papua New Guinea, Ghana, and U.S. The company was founded by William Boyce Thompson on May 2, 1921 and is headquartered in Denver, CO.

Newmont Corp

Newmont (NEM) is trending as investors digest recent Q3 earnings, which beat expectations despite a drop in gold prices impacting the stock. Community discussions revolve around the CEO's performance on the earnings call and the potential for manipulation by HFs. Despite mixed sentiment, many see long-term value, citing strong earnings and revenue beats.

Deckers Outdoor Corp. engages in the business of designing, marketing, and distributing footwear, apparel, and accessories developed for both everyday casual lifestyle use and high performance activities. It operates through the following segments: UGG Brand, HOKA Brand, Teva Brand, Sanuk Brand, Other Brands, and Direct-to-Consumer. The UGG Brand segment offers a line of premium footwear, apparel, and accessories. The HOKA Brand segment sells footwear and apparel that offers enhanced cushioning and inherent stability with minimal weight, originally designed for ultra-runners. The Teva Brand segment focuses on the sport sandal and modern outdoor lifestyle category, such as sandals, shoes, and boots. The Sanuk Brand segment originated in Southern California surf culture and has emerged into a lifestyle brand with a presence in the relaxed casual shoe and sandal categories. The Other Brands segment includes the Koolaburra by UGG brand. The Direct-to-Consumer segment consists of retail stores and e-commerce websites. The company was founded by Douglas B. Otto in 1973 and is headquartered in Goleta, CA.

Deckers Outdoor Corp.

Deckers Outdoor (DECK) is trending as investors assess its future following recent earnings and guidance. Community discussions revolve around concerns about slowing growth and the potential impact of tariffs, despite a solid earnings report. Some see the dip as a buying opportunity, citing the company's strong brands and potential for stock buybacks, while others express caution due to market uncertainty and broader economic factors.

$BALLIN is the perfect meme for everyone showing up every single day.  To be BALLIN, you gotta B-All-In.  The meaning to B All In doesn't only apply to the funds you invest.  It's about dedication.   The countless hours of research.   The endless raiding and working for your bags.  Not knowing how to quit while everyone is telling you you're wrong.  It's about believing in something.  Keep $BALLIN

B All In

B All In (BALLIN) is trending, with community members highlighting its strong momentum and potential for significant gains. The coin's association with Phantom Wallet and bullish chart patterns are key discussion points. Many users are expressing confidence and encouraging others to buy and hold.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as the community debates the stock's reaction to recent earnings and future prospects, particularly regarding AI and robotics. Discussions include Elon Musk's compensation package and its potential impact, as well as speculation about market manipulation. Community sentiment is divided between bulls citing long-term potential and bears pointing to valuation concerns.

Alaska Air Group, Inc. is a holding company, which engages in the provision of air transportation services. It operates through the following segments: Alaska Airlines, Hawaiian Airlines, and Regional. The Alaska Airlines segment includes scheduled air transportation on Alaska's Boeing and Airbus jet aircraft for passengers and cargo. The Hawaiian Airlines segment refers to scheduled air transportation on Hawaiian's Boeing and Airbus aircraft for passengers and cargo. The Regional segment consists of Horizon's and other third-party carriers’ scheduled air transportation on E175 aircraft for passengers under CPAs. The company was founded in 1985 and is headquartered in Seattle, WA.

Alaska Air Group Inc.

ALK is trending as investors await earnings, with some expressing concern over a potential delay in the release. Community members are analyzing option flows and debating whether bearish analysis will hold, or if the stock is poised for a pop. The airline sector's performance, including competitors like AAL, is also influencing sentiment.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG is trending as the community rallies around its fair launch and decentralized nature on the Bitcoin blockchain. Community members highlight its resilience during market corrections and tout the growing adoption by major players, like C2 Blockchain, accumulating $DOG for its treasury. The 'Dog Army' is actively pushing for broader exchange listings and celebrating its unique position within the Bitcoin ecosystem.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Next, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Next segment is involved in the expenses and investments for emerging business initiatives aimed at creating value for Ford in vehicle-adjacent market segments. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford is trending as community members discuss the company's recent earnings report, which beat expectations, and lowered guidance due to a supplier fire. Community sentiment seems mixed, with some expressing optimism about Ford's long-term potential, while others remain cautious due to lowered guidance and production impacts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MELBOURNE, Australia, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company,” NASDAQ: GELS), a clinical and science-based developer of gel-based oral delivery solutions, welcomes the recently&nbsp;announced product launches of <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=m_DdCQTpOIEkyMW6a_LTNu80nA-fvUjxL3WRLmnGS69pjlEjzE7uri5nWw8o-jN5ufZ7dm_TD-F_EgPyk3wUaQdHmXCqk3fv6wOqrJUixIc=">Healthy Extracts, Inc.</a>(“Healthy Extracts,” OTCQB: HYEX), whose products apply Gelteq’s proprietary gel technology, <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=jVTfFSVxnjolcQWdJUHguUDpIFQsKOiqOBXBpcPqudxVaqM7qCSY6qp7CcK5vPQJFCo7hIArwK5VrglasVoSV6fkl1MhXuC0Z8-hE_a4204rIsukKFHSs6N8s2fDFE3nNeNsvZBeBaVYTKiPqDW3LCAe7Pbvi1Ykp2jwWuGNhVBrcGVtaGDqvv_XCRaSX9V2pmGKXGiBfHNkQZ7JeBNpdl8KBByCsg5_bPZoMX49Lldu2oACh7Wdw4rKa5E1y6JJfaWZzk6107bQ3c5yeCotSV3KY6uN9ysKWvWsic3iFkfv13xMn1h_G_ovXuIFktP5">into the U.S. nutraceutical market</a>.The Healthy Extracts products are the first to reach Gelteq’s U.S. warehousing facility using Gelteq’s delivery platform, an important milestone that marks Gelteq’s transition from R&amp;D to active commercialization in the U.S. This development highlights both the growth potential of Gelteq’s technology in large-scale wellness markets in the U.S. and its ability to meet consumer demand for innovative, convenient, and clinically-informed formats.“We are pleased to see Gelteq’s technology expand into the U.S. market through our collaboration with Healthy Extracts,” said Nathan Givoni, CEO of Gelteq. “Healthy Extract’s launch demonstrates how our gels can be adapted to create differentiated, consumer-friendly solutions, while paving the way for additional products and partnerships across the U.S. market.”The collaboration with Healthy Extracts, first announced earlier this year, began with warehousing and fulfilment arrangements which laid the foundation for Gelteq's entry into the U.S. market. With this launch, the partnership with Healthy Extract has advanced into active sales and distribution, underscoring the growing momentum behind Gelteq’s gel delivery system and the potential for additional partnership opportunities in the U.S.About Gelteq Ltd.Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) is a clinical and science-based company dedicated to developing and commercialising gel-based oral delivery solutions for prescription drugs, nutraceuticals, pet care, sports nutrition, and other applications. Gelteq’s proprietary formulation technology aims to address challenges associated with conventional drug delivery, including taste masking, swallowing difficulties, and precision dosing. For more information, visit <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=CzDiesrgFr3dtr9zZyTAj8WQwqMRYCl9wExZjU5Avfu8KSGuGlzGWsggV7F94VXP7gCRfpAAoHjXJ2X5fMFejCkzv8bsd_YZymXULDOahWLGd0vI2gPkcqhcg17_0Yfr">www.gelteq.com</a>.Gelteq Contact: Investor Relations Matt Kreps, Darrow Associates IR +1-214-597-8200 mkreps@darrowir.comForward-Looking StatementsCertain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained herein are forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. For a discussion of these risks and uncertainties, refer to Gelteq’s filings with the U.S. Securities and Exchange Commission (“SEC”), including its Annual Report on Form 20-F filed on November 15, 2024 and its Registration Statement on Form F-1 initially filed with the SEC on July 1, 2025. Gelteq undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Gelteq Technology Powers U.S. Product Launches of its Nutraceutical Products for Partner

Gelteq has entered the U.S. market and transitioned from research and development to commercialization with the launch of gel-based products by its partner, Healthy Extracts.

Others

MELBOURNE, Australia, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solutions, today announced plans to commence a preclinical bioequivalence study in September 2025 to evaluate its novel gel-based formulation of a widely used antihistamine for allergy treatment. The study will be conducted by Adgyl Lifesciences (a partner of Eurofins Advinus), a leader in preclinical contract research services.If preclinical results are successful, Gelteq anticipates advancing to human clinical trials targeting U.S. Food and Drug Administration (FDA) approval via the 505(b)(2) regulatory pathway.“Our gel-based delivery platform is expected to transform traditional pharmaceutical products currently available on the market, especially where patient compliance and dosage control are critical,” said Nathan Givoni, CEO of Gelteq. “By applying our technology to a well-established antihistamine, we see a significant opportunity to capture value in the allergy market, where patient-friendly formats and flexible dosing remain unmet needs.”Allergic conditions affect over 50 million people annually in the United States alone (1). The global antihistamine market was valued at approximately USD $9 billion in 2023 growing at a 6% CAGR, projected to reach over USD $12 billion by 2028 (2). Demand spans paediatric, adult, and increasingly, animal health (3), reflecting the diverse applications for antihistamine therapies.Gelteq’s proprietary gel formulations aim to address key limitations of traditional tablets and syrups, including palatability challenges for children, swallowing difficulties for elderly patients, and precise dosing needs in veterinary medicine (3).“Our innovative gel technology offers potential advantages in taste masking, ease of administration, and flexible dosing,” added Mr. Givoni. “These attributes are particularly relevant in paediatrics and veterinary care where delivering effective allergy treatments can be challenging.”About Gelteq Ltd.Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) is a clinical and science-based company dedicated to developing and commercialising gel-based oral delivery solutions for prescription drugs, nutraceuticals, pet care, sports nutrition, and other applications. Gelteq’s proprietary formulation technology aims to address challenges associated with conventional drug delivery, including taste masking, swallowing difficulties, and precision dosing. For more information, visit <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=O19-A9YeYzwuzvF6uGAfqtDG5RRZjNh8mE7N1rM43qWuYEEherjJSFHi9Ncl812p3GbOQCQNBsWSS797RiLzww==">www.gelteq.com</a>.Gelteq Contact:Investor Relations Matt Kreps, Darrow Associates IR +1-214-597-8200 mkreps@darrowir.comForward-Looking StatementsCertain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained herein are forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. For a discussion of these risks and uncertainties, refer to Gelteq’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F filed on November 15, 2024. Gelteq undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.References<ol style="list-style-type:decimal;"><li>American College of Allergy, Asthma &amp; Immunology. (2023). Allergy facts. American College of Allergy, Asthma &amp; Immunology. <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=BNccLheL2BHDT5LVrxyDH2GA_gxthxCKK2am7PO7NqJTQcy2YC8ka5Kcte6IYk-_rkMMxzQMPvg2HqpjhYc9h72dvj8f127hx_V37sDA6KM=">https://acaai.org/allergies/</a></li><li>Grand View Research. (2024, March). Antihistamine market size, share &amp; trends analysis report. Grand View Research. <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=BNccLheL2BHDT5LVrxyDH8PA2iF4YPFOJnnXWrzLVPWX86_Wv7NSRcESK7JjTDN70jZpuPqpdsx_TBhsE_ulMsIgBJxpUBj13R4ETgeMYf2vk4jcPQISkwfsg1zYJE63DSmPuNhJhhBdTdUIzZKfJ9KWwDWruOryJwg7nm8RSHcuoR3YA-Wn6p7-YvPDoF3fCQ0atmiqwvReNLCbM7tPS-i_fie6yjzGM21gSt4TLW8X8McYSh-w8FfqP1mvol0z">https://www.grandviewresearch.com/industry-analysis/antihistamine-market</a></li><li>MarketsandMarkets. (2023, November). Veterinary dermatology drugs market by product, animal type, route of administration, end user – Global forecast to 2028. MarketsandMarkets. <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=BNccLheL2BHDT5LVrxyDH2Y1c895h1WrE2q8doDlYL1Ih6-5ysKO0PaJX-tphZJJStCjpjTLUUpMpUV9mhXVNK5FNLLa-zQHGWQ_B54syEdWd1IfeFXhWlqU7sjNYhquPgonhJoiVzv-ITdIV85I8IM23Z11Bfhxpq1a1_GLzd4eL402y-zBojIsxjwBqtdEDB_GkSWA1jEq6FQ_hAJ20teMk3pmiCXapAHCSC97v8t-RGifPW7uovJqJo2C_PfBuJyCntgc2WPWifTl4gP1FwrDiGwagc9NPUwLVWidNu47-s8qC0JOu9g0EzXQHXrvMq8x9Bg8Kt0gb5gX1HJARQ==">https://www.marketsandmarkets.com/Market-Reports/veterinary-dermatology-drugs-market-177021512.html</a></li></ol>Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Gelteq Announces Commencement of Preclinical Trial for Novel Gel-Based Antihistamine Formulation Targeting Allergy Market

Study to Support Potential FDA Approval via 505(b)(2) Pathway

Jul. 17, 2025 8:30 AM ET<a target="_blank" rel="noopener noreferrer nofollow" href="https://seekingalpha.com/symbol/GELS#source=section%3Amain_content%7Csection_asset%3Ameta%7Cfirst_level_url%3Aarticle%7Csymbol%3AGELS">Gelteq Limited (GELS)</a>GlobeNewswireNEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (<a target="_blank" rel="noopener noreferrer nofollow" href="https://seekingalpha.com/symbol/GELS#hasComeFromMpArticle=false#source=section%3Amain_content%7Cbutton%3Abody_link">GELS</a>) (“Gelteq” or the “Company”), a clinical and science-based company focused on developing and commercializing white label ingestible gel-based solutions for prescription drugs, nutraceuticals, pet care, sports and other products, today announced it has entered into a memorandum of understanding with IDT Australia (ASX: IDT) for a dedicated, locally based manufacturing facility to support the development and scale up of its gel-based products across diverse global pharmaceutical, nutraceutical and animal health markets.IDT is internationally recognized for its expertise in pharmaceutical projects and contract manufacturing services developed across more than 50 years of operation and over 60 market-based drugs. The company specializes in pharmaceutical product development and cGMP manufacture including high containment, high potency manufacture of Active Pharmaceutical Ingredients (API), oral and sterile dose FDA and TGA approved laboratory testing, and clinical packaging. IDT is also at the forefront of developing and manufacturing advanced therapies including mRNA and Antibody Drug Conjugates (ADCs).“Partnering with IDT to establish a locally-based, purpose-built manufacturing facility strategically positions Gelteq to accelerate and scale our products for the global nutraceutical, pharmaceutical and animal health markets,” said Nathan Givoni, CEO of Gelteq. “IDT not only brings proven development, manufacturing and regulatory expertise to support our goals, but also a unique knowledge base to speed up the development of new products targeting these markets.”Paul McDonald, CEO of IDT Australia, commented: “We are excited to combine IDT’s proven development and manufacturing capabilities with Gelteq’s innovative delivery system for wellness and therapeutic products. Gelteq’s proprietary gel technologies offer distinct benefits in both delivery and combination therapy opportunities needed to improve care and dosing compliance across many end markets.”Highlights of the Agreement:<ul><li>Facilities and Equipment required for the manufacture of Gelteq products, in a dedicated building and purpose-built facility, trained staff and operational support.</li><li>Compliance and Certification necessary for products in the therapeutic, veterinary and nutraceutical markets across various product presentations, including regulatory requirements, permits, and licenses from the APVMA, FDA, and TGA.</li><li>Rapid Scale Up Capability to integrate additional manufacturing space and equipment to support growth. &nbsp;</li></ul>About Gelteq Ltd. Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) is a clinical and science-based company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, sports and other products. Gelteq advances and commercializes its delivery solutions within five core verticals: pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications, and sports nutrition.The Company’s unique formulation directly addresses the issues associated with traditional drug delivery methods such as difficulty swallowing, taste of unpalatable ingredients, and dosage control. For more information, visit <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=00K18qA_R_h14eUsBeqQWCgMgMmxuWb3BtGKz6ILL5yQ1_R8YgVe3aEx_L8wLAZZPAeltknTuVaIh-pb4Kiy8g==">www.gelteq.com</a> and our SportsGel brand website <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=-p3-I0mUlJnWPMf-dUcDiLZEc5RjeyAm-S2zUBjuzZqsz6gVrldwGFhUq191BEReZ8bR_Byc31VTexJpTREpLHRAjbEauYCyxSObvUI2IKY=">www.sportsgel.com</a>.Gelteq Contact:&nbsp; Investor Relations Matt Kreps, Darrow Associates IR +1-214-597-8200 <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=lXdnLIhrjHSBfmEF8ctV8ZAmFeM-Ds7RVQBML108A473uXIgHycUxnGOSxVLrfBanFWPU-bmwMn1gK9Fn6lO2U8ADzIpjoyqaUQJQBtbSJM=">mkreps@darrowir.com</a>Forward-Looking Statements Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Gelteq’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the timing and fulfilment of current and future orders relating to Gelteq’s products, the success of new programs, the ability to implement a new strategic plan and the success of a new strategic plan. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Gelteq in general, see the risk factors in its Annual Report on 20-F filed on November 15, 2024. All such forward-looking statements speak only as of the date they are made, and Gelteq undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise.Source: Gelteq Limited 2025 GlobeNewswire, Inc.Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Gelteq Announces Agreement with IDT Australia to Secure Dedicated New Product Development and Manufacturing Facilities

https://seekingalpha.com/pr/20169476-gelteq-announces-agreement-with-idt-australia-to-secure-dedicated-new-product-development-and

Shares of Gelteq (GELS) soared 71% on Tuesday afternoon after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.gelteq.com/news-events/press-releases/detail/103/gelteq-expands-u-s-operations-with-healthy-extracts-inc">announced</a> an exclusive logistics and distribution agreement with Healthy Extracts Inc. in a bid to expand operations in North America.The agreement names Healthy Extracts as Gelteq’s exclusive North American storage, shipping, and fulfillment partner. Healthy Extracts is a publicly traded company focused on plant-based health supplements.Gelteq expects to rapidly scale the distribution of its white-label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, sports, and other products across the United States and Canada, while significantly reducing costs and boosting revenue potential.Under the new agreement, Healthy Extracts will manage all product receiving, secure warehousing, inventory, and order fulfillment from its Henderson, Nevada, facility. The collaboration is expected to reduce fulfillment costs and unlock high-margin revenue opportunities for both Gelteq and Healthy Extracts.“We believe this is a scalable, profitable model for both companies and our shareholders,” said Duke Pitts, President of Healthy Extracts.The initial products to be received under this new agreement are on track for market distribution by the third quarter (Q3) of 2025.On Stocktwits, retail sentiment around Gelteq jumped from ‘extremely bearish’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:628/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_10_at_1_19_18_PM_png_58ec493774.webp" alt="GELS's Sentiment Meter and Message Volume as of 1:15 p.m. ET on June 10, 2025 | Source: Stocktwits" width="628" height="64"><figcaption>GELS's Sentiment Meter and Message Volume as of 1:15 p.m. ET on June 10, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/GELS">GELS stock</a> is up by about 22% this year and down by about 1% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/us-fda-places-clinical-hold-on-gilead-trials-of-two-investigational-hiv-treatments/chl7qNLRbzY">US FDA Places Clinical Hold On Gilead Trials Of Two Investigational HIV Treatments: Retail’s On The Fence</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Gelteq Stock Soars On Deal With Healthy Extracts For Product Distribution In North America: Retail Chatter Explodes

The agreement names Healthy Extracts as Gelteq’s exclusive North American storage, shipping, and fulfillment partner.

Equity

Gelteq Ltd. operates as a biotechnology company. It focuses on the development and commercialization of white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and other products. The firm also offers edible gels. The company was founded by Nathan J. Givoni and Simon H. Szewach on October 15, 2018 and is headquartered in Melbourne, Australia.

GELS
Gelteq Ltd.

Feed

News

Sentiment

Fundamentals

Info

Latest GELS News

GELSGelteq Ltd.